Galway based medical device company Perfuze raises €22.5m for stroke treatment device.

Perfuze is developing catheter-based technology to treat acute ischemic stroke by removing blood clots from the brain in a single pass.

The funds will be utilized to advance the next stage of its Millipede catheter-based technology’s clinical trial and regulatory clearance in the United States. The funding will also aid in the development of new goods and the commercialization of the company’s technology.

The Millipede technology developed by the Irish medtech start-up was granted breakthrough device classification by the US Food and Drug Administration in 2019. Medical devices that potentially provide a more effective treatment for life-threatening or profoundly disabling diseases are given this certification.

Perfuze strives to deliver better results in less time, ensuring a safe and cost-effective therapy. According to the World Health Organization, stroke is the second largest cause of death and disability worldwide. An ischemic stroke happens when a clot blocks a blood vessel in the brain, limiting blood flow.

According to Micheál Coughlan, Managing Partner InterSearch Ireland and Global Leader Medical Practice Group InterSearch Worldwide “Perfuze is part of a successful eco-system of entrepreneurial medical device companies operating from the West of Ireland with the potential for a significant impact on the treatment of ischemic stroke globally”.

We use cookies to give you the best online experience. By agreeing you consent the use of cookies in accordance with our Privacy Statement and cookie settings in your Privacy Settings below.

Privacy Settings saved!
Privacy Settings

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie

Decline all Services
Accept all Services